AKT1 and colitis: Previous studies have also reported that exhibits a therapeutic effect in experimental colitis by inhibiting the CEBPB/PCK1 and CEBPB/EFNA1 pathways, which are associated with the PI3K-Akt and P38 MAPK pathways [32].